Lista de obras -

ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome

artículo científico publicado en 2009

Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility.

artículo científico publicado en 2010

Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation.

artículo científico publicado en 2006

C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation

artículo científico publicado en 2007

Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: not simply overestimation

artículo científico publicado en 2005

Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients

Cyclosporine formulation and Kaposi's sarcoma after renal transplantation

artículo científico publicado en 2005

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy

artículo científico publicado en 2014

Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation

artículo científico publicado en 2002

In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development.

artículo científico publicado en 2013

In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the MY.S.S. Trial

artículo científico publicado en 2004

Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study

article

Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration

artículo científico publicado en 2019

Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen.

artículo científico publicado en 2009

Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy.

artículo científico publicado en 2018

Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation.

artículo científico publicado en 2013

Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial

artículo científico publicado en 2004

Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.

artículo científico publicado en 2007

Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients

artículo científico publicado en 2006

Omega-3 polyunsaturated fatty acids affect sirolimus exposure in kidney transplant recipients on calcineurin inhibitor-free regimen

artículo científico publicado en 2010

Paricalcitol for secondary hyperparathyroidism in renal transplantation

artículo científico publicado en 2014

Pharmacokinetic/pharmacodynamic drug interaction between rosiglitazone and mycophenolate mofetil in kidney transplantation: a case report

artículo científico publicado en 2008

Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients

artículo científico publicado en 2007

Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs

artículo científico publicado en 2007

Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings

artículo científico publicado en 2003

Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.

artículo científico publicado en 2007

The Bergamo Kidney Transplant Program.

artículo científico publicado en 2005

Lista de obras de

ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome

Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility.

Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation.

C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation

Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: not simply overestimation

Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients

Cyclosporine formulation and Kaposi's sarcoma after renal transplantation

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy

Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation

In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development.

In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the MY.S.S. Trial

Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study

Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration

Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen.

Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy.

Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation.

Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial

Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.

Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients

Omega-3 polyunsaturated fatty acids affect sirolimus exposure in kidney transplant recipients on calcineurin inhibitor-free regimen

Paricalcitol for secondary hyperparathyroidism in renal transplantation

Pharmacokinetic/pharmacodynamic drug interaction between rosiglitazone and mycophenolate mofetil in kidney transplantation: a case report

Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients

Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs

Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings

Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.

The Bergamo Kidney Transplant Program.

Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation